Cash, cash equivalents and marketable securities were $677.5 million as of March 31, 2025. The company expects that its cash, cash equivalents and marketable securities as of March 31, 2025 will be sufficient to fund its operations at least into the second half of 2026.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Biotech Alert: Searches spiking for these stocks today
- Dyne Therapeutics receives EMA orphan drug designation for DYNE-251
- RBC sees Makary interview as potentially positive for biotech stocks
- Dyne Therapeutics appoints Ranade as CBO, Batra as CSO